Comparison · NCT01313663-bd75516d
Pemetrexed 500 mg/m^2 vs Pazopanib 800 mg: Number of Participants With Any AE (Serious or Non-serious) Leading to Withdrawal From Study Treatment
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pemetrexed 500 mg/m^2 vs Pazopanib 800 mg: Number of Participants With Any AE (Serious or Non-serious) Leading to Withdrawal From Study Treatment. Trial comparisons, record NCT01313663-bd75516d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01313663-bd75516d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.222 | 0.0632 | 0.547 | wilson | |
| Risk in group 2 | 0.2 | 0.0567 | 0.51 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0222 | -0.326 | 0.378 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.11 | 0.195 | 6.34 | log | |
| Odds ratio, group 1 over group 2 | 1.14 | 0.126 | 10.4 | log | |
| Number needed to treat, for one more participant with the outcome on Pemetrexed 500 mg/m^2 than on Pazopanib 800 mg | 45 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pemetrexed 500 mg/m^2 | Participants received an intravenous (IV) infusion of pemetrexed (500 mg per meters squared \[mg/m\^2\]) over 10 minutes on Day 1 of each 21-day cycle. Participants received study treatment until disease progression, death, unacceptable adverse event, withdrawal of consent, or physician decision. Participants who withdrew due to an adverse event or disease progression were followed for survival. | 2 | 9 | OG000 |
| Group 2 | Pazopanib 800 mg | Participants received pazopanib 800 milligrams (mg) orally once a day at approximately the same time each day, either 1 hour before a meal or 2 hours after a meal. The tablets were to be swallowed whole and were not to be crushed or broken. Participants received study treatment until disease progression, death, unacceptable adverse event, withdrawal of consent, or physician decision. Participants who withdrew due to an adverse event or disease progression were followed for survival. | 2 | 10 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Any AE (Serious or Non-serious) Leading to Withdrawal From Study Treatment
- Description
An AE is defined as any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect. In addition, all Grade 4 laboratory abnormalities and other medically important events that require medical or surgical intervention to prevent one of the outcomes listed previously are considered to be SAEs. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs. A participant cold have been withdrawn fom study treatment due to an SAE or AE.
- Time frame
- From the time the first dose of study treatment was administered until withdrawal from study treatment (up to Study Week 55)
- Population
- Safety Population
Source ClinicalTrials.gov
Trial
- Title
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
- NCT number
- NCT01313663
- Phases
- PHASE2
- Conditions
- Lung Cancer, Small Cell
- Interventions
- pazopanib, pemetrexed
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2013-04-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01313663?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01313663-bd75516d